Responses
Regular and young investigator award abstracts
Checkpoint blockade therapy
206 An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
